View:
United States securities and exchange commission logo
December 1, 2020
Nima M. Farzan
President and Chief Executive Officer
Kinnate Biopharma Inc.
11875 El Camino Real, Suite 101
San Diego, California 92130
Re: Kinnate Biopharma
Inc.
Amendment No. 1 to
Registration
Statement on Form S-1
Filed November 30,
2020
File No. 333-250086
Dear Ms. Farzan:
We have reviewed your amended registration statement and have
the following
comment. Please respond to this letter by amending your registration
statement and providing
the requested information. If you do not believe our comment applies to
your facts and
circumstances or do not believe an amendment is appropriate, please tell
us why in your
response.
After reviewing any amendment to your registration statement and
the information you
provide in response to the comment, we may have additional comments.
Amendment No. 1 to Registration Statement on Form S-1
Use of Proceeds, page 82
1. We reissue comment 2.
Revise to state how much of the proceeds of the offer will be
used to "initiate and
complete [y]our planned Phase 1 clinical trial of KIN002787," how
much will be used to
"initiate [y]our planned Phase 1 clinical trial of KIN003," what
additional funds will
be needed to complete the Phase 1 trial of KIN003, and what portion
of the proceeds will go
to other RAF product candidates, other FGFR product candidates,
and other uses.
Nima M. Farzan
FirstName LastNameNima
Kinnate Biopharma Inc. M. Farzan
Comapany1,
December NameKinnate
2020 Biopharma Inc.
December
Page 2 1, 2020 Page 2
FirstName LastName
You may contact Julie Sherman at (202) 551-3640 or Angela Connell at
(202) 551-
3426 if you have questions regarding the financial statements and related
matters. Please contact
Abby Adams at (202) 551-6902 or Celeste Murphy at (202) 551-3257 with any other
questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Tony Jeffries, Esq.